Back to Browse Journals » Clinical Interventions in Aging » Volume 4

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

Authors Paula Rackoff

Published Date May 2009 Volume 2009:4 Pages 207—213

DOI http://dx.doi.org/10.2147/CIA.S4080

Published 5 May 2009

Paula Rackoff

Division of Rheumatology, Beth Israel Medical Center, New York, NY, USA

Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.

Keywords: osteoporosis, fracture

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read: